This article from Forbes reports on a new venture capital fund started by three former executives of Millennium Pharmaceuticals: Mark Levin, Kevin Starr, and Bob Tepper. They just raised $378 million for what they're calling Third Rock Ventures. According to the article, the fund will be closely managing startup companies, and will "only look at a few biotechs, each getting a few tens of millions of dollars."

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.